Wednesday, December 31, 2025 | 02:42 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Pfizer Ltd News

Cipla to exclusively market and distribute five Pfizer brands in India

Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk

Cipla to exclusively market and distribute five Pfizer brands in India
Updated On : 19 Dec 2025 | 7:20 PM IST

Pfizer, Cipla sign exclusive marketing, distribution deal for 4 brands

Cipla Ltd has inked an exclusive agreement with Pfizer India to market, distribute, and sell the latter's four brands across the country. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the two companies said in a joint statement on Friday. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India, they added. It is the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer's medicines widely available across India by combining its well-established portfolio with Cipla's deep market reach, the statement said. Pfizer India Country President Meenakshi Nevatia said the partnership with Cipla will help expand the reach of its medicines to patients. "With Pfizer's legacy of breakthroughs, quality and innovation, and

Pfizer, Cipla sign exclusive marketing, distribution deal for 4 brands
Updated On : 19 Dec 2025 | 2:55 PM IST

Pfizer launches Rimegepant ODT in India to tap $200 mn migraine market

Pfizer has introduced Rimegepant ODT for adults who do not respond well to triptans, entering a migraine market nearing $200 million, projected to double by 2030 as India faces rising disease burden

Pfizer launches Rimegepant ODT in India to tap $200 mn migraine market
Updated On : 17 Nov 2025 | 7:44 PM IST

Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally
Updated On : 01 Oct 2025 | 9:59 AM IST

Pfizer share price up 3% on rolling out this vaccine; key details inside

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.

Pfizer share price up 3% on rolling out this vaccine; key details inside
Updated On : 12 Aug 2025 | 9:51 AM IST

Dividend stocks: Pfizer, 6 others to go ex-date on July 9; do you own any?

Here is the complete list of stocks that will trade ex-dividend on July 9, following their announcements of dividend rewards for shareholders

Dividend stocks: Pfizer, 6 others to go ex-date on July 9; do you own any?
Updated On : 08 Jul 2025 | 7:56 AM IST